Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

12

Possibly Marketed Outside US

11

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Iron

2

Protein cereblon

2

26S proteosome

1

A673

1

Bcr/Abl fusion protein

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

11

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2005

2

2008

2

2009

2

2015

2

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Multiple myeloma

5

Mantle cell lymphoma

2

Aggressive systemic mastocytosis (D816V c-Kit mutation status negative/c-Kit mutational status unknown)

1

Beta-thalassemia

1

Dermatologic infections

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

10

Secondary

2

Diagnostic

1

Preventing

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

5

CNS Active

3

CNS Non-penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Novartis

2

BASF

1

Bristol-Myers Squibb

1

Celgene

1

EntreMed|National Cancer Institute|National Institute of Allergy and Infectious Diseases|National Institutes of Health|University of Pennsylvania

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Protein

12

Chemical

11

Concept

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

EMA ASSESSMENT REPORTS

24

EVMPD

24

FDA UNII

23

NCI_THESAURUS

23

CAS

22

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

COAGULATION FACTOR

2

CYTOKINE

1

ENZYME

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

6

BLOOD AND BLOOD FORMING ORGANS

6

VARIOUS

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIHEMORRHAGICS

5

ALL OTHER THERAPEUTIC PRODUCTS

3

ANTINEOPLASTIC AGENTS

2

IMMUNOSTIMULANTS

2

IMMUNOSUPPRESSANTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

VITAMIN K AND OTHER HEMOSTATICS

5

ALL OTHER THERAPEUTIC PRODUCTS

3

IMMUNOSTIMULANTS

2

IMMUNOSUPPRESSANTS

2

OTHER ANTINEOPLASTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Blood coagulation factors

5

Iron chelating agents

2

Other antineoplastic agents

2

Other immunosuppressants

2

Antidotes

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

19

Salts, Hydrates, Esters, etc.

4

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "EMA EPAR|DISEASES|BLOOD AND LYMPHATIC DISEASES|HEMATOLOGIC DISEASES" in comments (approximate match)

Showing 11 - 20 of 24 results

First page
Previous page
2
Next page
Next page

CATRIDECACOG

NU23Q531G1

Subunit 1 (731) Similarity Search Subunit 2 (731) Similarity Search

Export Data
Sequence Search

Subunit 1 (731) Similarity Search Subunit 2 (731) Similarity Search

Status:

Possibly Marketed Outside US

First approved in 2013

Class:

PROTEIN

ANTITHROMBIN ALFA

AWV6I5L6H2

Subunit 1 (432) Similarity Search

Export Data
Sequence Search

Subunit 1 (432) Similarity Search

Status:

Possibly Marketed Outside US

First approved in 2009

Class:

PROTEIN

VON WILLEBRAND FACTOR HUMAN

ZE22NE22F1

Subunit 1 (2050) Similarity Search

Export Data
Sequence Search

Subunit 1 (2050) Similarity Search

Status:

Possibly Marketed Outside US

First approved in 2009

Class:

PROTEIN

MOROCTOCOG ALFA

113E3Z3CJJ

Subunit 1 (754) Similarity Search Subunit 2 (684) Similarity Search

Export Data
Sequence Search

Subunit 1 (754) Similarity Search Subunit 2 (684) Similarity Search

Status:

Possibly Marketed Outside US

First approved in 2008

Class:

PROTEIN

COAGULATION FACTOR VIIA RECOMBINANT HUMAN

AC71R787OV

Subunit 1 (254) Similarity Search Subunit 2 (152) Similarity Search

Export Data
Sequence Search

Subunit 1 (254) Similarity Search Subunit 2 (152) Similarity Search

Status:

Possibly Marketed Outside US

First approved in 1999

Class:

PROTEIN

ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT

P89DR4NY54

Subunit 1 (1313) Similarity Search Subunit 2 (684) Similarity Search

Export Data
Sequence Search

Subunit 1 (1313) Similarity Search Subunit 2 (684) Similarity Search

Status:

Possibly Marketed Outside US

First approved in 1993

Class:

PROTEIN

COAGULATION FACTOR IX HUMAN

6U90Y1795T

Subunit 1 (415) Similarity Search

Export Data
Sequence Search

Subunit 1 (415) Similarity Search

Status:

Possibly Marketed Outside US

First approved in 1990

Class:

PROTEIN

ANTIHEMOPHILIC FACTOR HUMAN

839MOZ74GK

Subunit 1 (1313) Similarity Search Subunit 2 (684) Similarity Search

Export Data
Sequence Search

Subunit 1 (1313) Similarity Search Subunit 2 (684) Similarity Search

Status:

Possibly Marketed Outside US

First approved in 1988

Class:

PROTEIN

TUROCTOCOG ALFA

969NZA3X9T

Subunit 1 (761) Similarity Search Subunit 2 (684) Similarity Search

Export Data
Sequence Search

Subunit 1 (761) Similarity Search Subunit 2 (684) Similarity Search

Status:

Possibly Marketed Outside US

Class:

PROTEIN

Imatinib Mesylate

8A1O1M485B

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2001

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Platelet-derived growth factor receptor alpha

Platelet-derived growth factor receptor beta

Stem cell growth factor receptor

Bcr/Abl fusion protein

Conditions:

Myelodysplastic/myeloproliferative diseases associated with PDGFR

Hypereosinophilic syndrome

Philadelphia chromosome positive chronic myeloid leukemia

Philadelphia chromosome positive acute lymphoblastic leukemia

Aggressive systemic mastocytosis (D816V c-Kit mutation status negative/c-Kit mutational status unknown)

Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It...

inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive CML. Imatinib (GLEEVEC®) inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. It is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib (GLEEVEC®) inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.

Showing 11 - 20 of 24 results

First page
Previous page
2
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1